BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Protein Mechanics, Inc. And Aventis S.A. (AVE) Enter Research Collaboration; Protein Mechanics To Help In Lead Identification Of Novel And Selective Inhibitors


10/19/2005 5:10:34 PM

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--March 23, 2004--Protein Mechanics, Inc., and Aventis have entered into an agreement to advance the identification, discovery and validation of highly selective, orally available matrix metalloprotease (MMP) inhibitors, a promising new class of drugs for treatment of a broad array of pathologies involving the extracellular matrix.

The large MMP family has been implicated in solid tumor growth, atherosclerosis, rheumatoid arthritis and Alzheimer's disease, as well as in corneal, periodontal and dermatological disorders. However, these closely related targets present significant selectivity challenges when approached with conventional methods. Protein Mechanics will utilize its Imagiro(R) predictive simulation technology to provide Aventis with insights into important aspects of specific target-ligand interaction, including novel binding sites, binding modes, mechanisms of action and induced-fit conformational changes, in order to drive design and optimization of highly selective drug leads.

"Aventis has a strong record of commitment and accomplishment in the development of novel therapeutics for important disease areas, so we are extremely gratified that it has chosen Protein Mechanics as a partner in this effort," said Ken Haas, President and CEO of Protein Mechanics, Inc. "We have been particularly impressed with Aventis' work in selective metalloprotease inhibition and their expertise in applying novel technologies to critical aspects of drug discovery, so we are highly energized by the onset of our collaboration."

Financial terms of the agreement were not disclosed.

About Protein Mechanics

Protein Mechanics is a drug discovery company using ground-breaking predictive simulation technology to design novel small molecule therapeutics against difficult, high value targets. The Company's unique technology allows medicinal chemists to use capabilities such as direct observation of conformational change and rapid determination of binding affinities to discover new mechanisms of action, new binding sites and new compounds or scaffolds. Protein Mechanics intends to pursue certain targets on behalf of corporate pharmaceutical partners using its discovery technology to help generate lead compounds in multiple disease areas. In addition, the Company will selectively pursue other compounds and targets for internal development. Established in 2001, Protein Mechanics, Inc., is a privately held biotechnology company headquartered in Mountain View, California.

For more information, please visit: www.ProteinMechanics.com

Contacts

Protein Mechanics, Inc. Michael Hollars, 408-472-5655 contact@proteinmechanics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES